Search

Your search keyword '"Kimoto Aishi"' showing total 31 results
Start Over Author "Kimoto Aishi"
31 results on '"Kimoto Aishi"'

11. Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis

Author

Tanaka, Makoto, primary, Mori, Hiroshi, additional, Shimizu, Kiyoshi, additional, Matsuoka, Toshiyuki, additional, Yamamotoya, Hajime, additional, Minamide, Toshiomi, additional, Mori, Masamichi, additional, Nozaki, Kazutoshi, additional, Usui, Takashi, additional, Shimokawa, Kenichiro, additional, Suzuki, Hiromi, additional, Aoyama, Koji, additional, Kimoto, Aishi, additional, Sasamata, Masao, additional, and Miyata, Keiji, additional

Published
2009
Full Text
View/download PDF

12. Removal of extracellular Mg2+ suppresses sulfation of glycoconjugates secreted from rabbit trachea in culture

Author

Kai Hirofumi, Kimoto Aishi, Yoshitake Kazuhisa, Matsumoto Sachiko, Isohama Yoichiro, Takahama Kazuo, and Miyata Takeshi

Subjects
Pharmacology, Male, Glucosamine, Chondroitin Lyases, Sulfates, Chondroitin Sulfates, Temperature, Sulfur Radioisotopes, Trachea, Organ Culture Techniques, Animals, Magnesium, Rabbits, Energy Metabolism, Glucosidases, Glycogen
Abstract

The influences of extracellular Ca2+ and Mg2+ concentrations on the basal secretion of glycoconjugates from rabbit trachea in organ culture were examined. Over 80% of the 35S-labeled and [3H]glucosamine-labeled glycoconjugates secreted by the trachea were digested upon incubation with chondroitinase ABC. The basal secretion did not occur in the medium at 4 degrees C, indicating an energy-dependent process. The basal secretion at 37 degrees C of 35S-labeled glycoconjugates was prominently suppressed in Mg(2+)-free Tyrode solution but not in Ca(2+)-free Tyrode solution containing ethyleneglycol bis(2-aminoethylether)tetraacetic acid (EGTA). In contrast, the basal secretion of [3H]glucosamine-labeled glycoconjugates was not affected by the Mg2+ concentration in the medium. The results suggest that extracellular Mg2+ largely contributes to sulfation of glycoconjugates basally secreted from rabbit trachea.

Published
1992

14. Suppression of Adjuvant-Induced Arthritic Bone Destruction by Cyclooxygenase-2 Selective Agents With and Without Inhibitory Potency Against Carbonic Anhydrase II

Author

Katagiri, Mika, primary, Ogasawara, Toru, additional, Hoshi, Kazuto, additional, Chikazu, Daichi, additional, Kimoto, Aishi, additional, Noguchi, Masahiro, additional, Sasamata, Masao, additional, Harada, Shun-ichi, additional, Akama, Hideto, additional, Tazaki, Hatsue, additional, Chung, Ung-il, additional, Takato, Tsuyoshi, additional, Nakamura, Kozo, additional, and Kawaguchi, Hiroshi, additional

Published
2006
Full Text
View/download PDF

20. The Effects of YM26818 : 1-(2-Dimethylaminoethyl)-1-(3, 4, 5-trimethoxyphenyl) urea and Derivatives on Pulmonary Surfactant Secretion and Lung Compliance

Author

KIMOTO, Aishi, primary, SAITO, Munetoshi, additional, HIRANO, Yasuno, additional, IWAI, Takaya, additional, TOMIOKA, Kenichi, additional, YAMADA, Toshimitsu, additional, MIYATA, Keiji, additional, MARUYAMA, Tatsuya, additional, IMANISHI, Naoki, additional, HARA, Hiromu, additional, and MASE, Toshiyasu, additional

Published
1998
Full Text
View/download PDF

22. Pharmacological Profile of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor.

Author

Yoshino, Taiji, Kimoto, Aishi, Kobayashi, Seiji, Noguchi, Masahiro, Fukunaga, Masahiro, Hayashi, Asuka, Miyata, Keiji, and Sasamata, Masao

Subjects
CELECOXIB, CYCLOOXYGENASE 2 inhibitors, ANTI-inflammatory agents, PHARMACOLOGY, CLINICAL medicine, MEDICAL research
Abstract

The pharmacological profile of celecoxib (CAS 169590-42-5, SC-58635), a specific cyclooxygenase-2 (COX-2) inhibitor, was investigated. Celecoxib inhibited COX-2-mediated prostaglandin E2 (PGE2) production in human dermal fibroblasts (IC50 = 91 nmol/l), whereas it was a weak inhibitor of COX-1-mediated PGE2 production in human lymphoma cells (IC50 = 2800 nmol/l). In in vivo studies, the effects of celecoxib were compared with those of nonsteroidal anti-inflammatory drugs (NSAIDs) in acute rat models of hyperalgesia and pyrexia. Celecoxib abrogated carrageenan-induced hyperalgesia in the hind paw accompanied by a decrease in PGE2 content in paw exudates and cerebrospinal fluid in a dose-related manner, with an ED30 = 0.81 mg/kg. Its analgesic potency was comparable to those of NSAIDs. In lipopolysaccharide-induced pyrexia, the anti-pyretic potency of celecoxib was equal to that of NSAIDs. On the other hand, in a gastric toxicity study in rats, single oral administration of celecoxib had no effect on gastric mucosa or mucosal PGE2 content at doses up to 200 mg/kg. Additionally, celecoxib did not inhibit thromboxane B2 production of calcium ionophore-stimulated peripheral blood of rats or arachidonic acid-induced aggregation of human platelets. These findings suggest that celecoxib might be a safe and effective alternative to NSAIDs for clinical use. [ABSTRACT FROM AUTHOR]

Published
2005

28. Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.

Author

Tanaka M, Mori H, Shimizu K, Toshiyuki, Matsuoka, Yamamotoya H, Minamide T, Mori M, Nozaki K, Usui T, Shimokawa K, Suzuki H, Aoyama K, Kimoto A, Sasamata M, and Miyata K

Subjects
Animals, Bone Density drug effects, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents pharmacokinetics, Bone Remodeling drug effects, Bone Resorption drug therapy, Clinical Trials as Topic, Diphosphonates administration & dosage, Diphosphonates pharmacokinetics, GTP-Binding Proteins metabolism, Geranyltranstransferase antagonists & inhibitors, Humans, Imidazoles administration & dosage, Imidazoles pharmacokinetics, Mevalonic Acid metabolism, Spinal Fractures prevention & control, Bone Density Conservation Agents pharmacology, Bone Density Conservation Agents therapeutic use, Diphosphonates pharmacology, Diphosphonates therapeutic use, Imidazoles pharmacology, Imidazoles therapeutic use, Osteoporosis drug therapy
Published
2009
Full Text
View/download PDF

31. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.

Author

Yoshino T, Kimoto A, Kobayashi S, Noguchi M, Fukunaga M, Hayashi A, Miyata K, and Sasamata M

Subjects
Animals, Carrageenan, Celecoxib, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Dinoprostone biosynthesis, Fever chemically induced, Fever drug therapy, Fibroblasts drug effects, Fibroblasts metabolism, Humans, Hyperalgesia chemically induced, Hyperalgesia drug therapy, In Vitro Techniques, Interleukin-1 pharmacology, Lipopolysaccharides, Lymphoma metabolism, Male, Membrane Proteins, Platelet Aggregation drug effects, Rats, Rats, Sprague-Dawley, Stomach Ulcer chemically induced, Stomach Ulcer pathology, Thromboxane B2 biosynthesis, Tumor Cells, Cultured, Cyclooxygenase Inhibitors pharmacology, Prostaglandin-Endoperoxide Synthases metabolism, Pyrazoles pharmacology, Sulfonamides pharmacology
Abstract

The pharmacological profile of celecoxib (CAS 169590-42-5, SC-58635), a specific cyclooxygenase-2 (COX-2) inhibitor, was investigated. Celecoxib inhibited COX-2-mediated prostaglandin E2 (PGE2) production in human dermal fibroblasts (IC50 = 91 nmol/l), whereas it was a weak inhibitor of COX-1-mediated PGE2 production in human lymphoma cells (IC50 = 2800 nmol/l). In in vivo studies, the effects of celecoxib were compared with those of nonsteroidal anti-inflammatory drugs (NSAIDs) in acute rat models of hyperalgesia and pyrexia. Celecoxib abrogated carrageenan-induced hyperalgesia in the hind paw accompanied by a decrease in PGE2 content in paw exudates and cerebrospinal fluid in a dose-related manner, with an ED30 = 0.81 mg/kg. Its analgesic potency was comparable to those of NSAIDs. In lipopolysaccharide-induced pyrexia, the anti-pyretic potency of celecoxib was equal to that of NSAIDs. On the other hand, in a gastric toxicity study in rats, single oral administration of celecoxib had no effect on gastric mucosa or mucosal PGE2 content at doses up to 200 mg/kg. Additionally, celecoxib did not inhibit thromboxane B2 production of calcium ionophore-stimulated peripheral blood of rats or arachidonic acid-induced aggregation of human platelets. These findings suggest that celecoxib might be a safe and effective alternative to NSAIDs for clinical use.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results